Flexion Q4 revenue up 36%; shares down 19% after hours on Zilretta outlook

|About: Flexion Therapeutics, ... (FLXN)|By:, SA News Editor

On a preliminary basis, Flexion Therapeutics (NASDAQ:FLXN) generated $9.5M in revenue in Q4, up 36% yoy. Full-year revenue was ~$22.5M.

The company expects ZILRETTA (triamcinolone acetonide) sales this year of $65M - 80M.

Management will host a conference call tomorrow, January 4, at 8:30 am ET to discuss the results and outlook.

Shares are down 19% after hours in apparent reaction to its ZILRETTA outlook.

Subscribe for full text news in your inbox